Merck & Co Inc (MRK)

MRK (NYSE:Drugs) EQUITY
$63.01
pos +0.16
+0.25%
Today's Range: 62.64 - 63.29 | MRK Avg Daily Volume: 9,991,600
Last Update: 08/29/16 - 3:59 PM EDT
Volume: 5,509,513
YTD Performance: 18.99%
Open: $62.95
Previous Close: $62.85
52 Week Range: $47.97 - $64.00
Oustanding Shares: 2,765,208,203
Market Cap: 172,327,775,211
6-Month Chart
TheStreet Ratings Grade for MRK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 4 5 5
Moderate Buy 0 0 0 0
Hold 7 8 7 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.08 2.33 2.17 2.17
Latest Dividend: 0.46
Latest Dividend Yield: 2.95%
Dividend Ex-Date: 09/13/16
Price Earnings Ratio: 34.24
Price Earnings Comparisons:
MRK Sector Avg. S&P 500
34.24 34.40 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
11.46% 15.49% 31.98%
GROWTH 12 Mo 3 Yr CAGR
Revenue -6.50 -0.20 -0.06
Net Income -62.60 -0.30 -0.11
EPS -61.70 -0.20 -0.08
Earnings for MRK:
EBITDA 13.92B
Revenue 39.50B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $0.98 $0.95 $3.74 $3.75
Number of Analysts 6 5 10 10
High Estimate $1.01 $0.97 $3.78 $3.89
Low Estimate $0.96 $0.92 $3.68 $3.49
Prior Year $0.96 $0.93 $3.59 $3.74
Growth Rate (Year over Year) 2.43% 1.72% 4.04% 0.54%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
The market continues to defy those players who believe we are seeing the calm before the storm.
Besides Tesla, Twitter and Biogen make good candidates.
There's a price to pay for low expectations.
BMY is unlikely to stay in the low $60s for long.
The failed trial is among the biggest single blows by a major pharma player.
Rising crude prices help buoy a host of oil companies Monday.
One day does not make a trend, but one day can certainly reinforce an existing trend.
Mattress Firm soars on takeover bid, while Delta's worldwide computer issues are causing the stock to drop.
Bullish
Aug 08, 2016 | 7:16 AM EDT
MRK was upgraded to Outperform, Credit Suisse said. $73 price target. Keytruda stands to benefit from recent setback for Opdivo.
BMY's loss definitely looks like MRK's gain.

Columnist Conversations

The Emini S&P 500 (ES) is grinding higher off of Friday's Fischer Low at 2157.50 into the August sideways ...
Mylan (MYL) says the "generic" EpiPen will be identical to the current one at about half the price. (Same pro...
There is a long term zone of support on the weekly chart of the PowerShares DB US Dollar Bullish ETF (UUP...
Market off to a decent start with all three major indices slightly up even as oil begins the week with over a ...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.